A federal judge has ruled that a qui tam suit on behalf of more than two dozen states, accusing a Johnson & Johnson subsidiary of off-label marketing of HIV/AIDS drugs, can move ahead in pared-down form.

U.S. District Judge Michael Shipp, granting in part and denying in part a summary judgment motion, ruled May 30 that some claims against Janssen Products can proceed.

At the same time, Shipp dismissed all claims against J&J itself, holding that “mere ownership” of a subsidiary does not make for claims against the parent.